MANTLE CELL LYMPHOMA (MCL)

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This study is testing a new combination of three targeted drugs (orelabrutinib, lisaftoclax, and rituximab) for people newly diagnosed with a high-risk form of mantle cell lymphoma, an aggressive blood cancer. The goal is to see if this combination can effectively control the dis…

This study is testing a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goal is to see how well this combination clears the body of tiny amounts of leftover cancer cell…

This study is testing a combination of two drugs, orelabrutinib and rituximab, for people newly diagnosed with a type of blood cancer called mantle cell lymphoma (MCL). The main goal is to see how well this treatment can put the cancer into complete remission. Researchers will al…

This is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …

This international study is testing a new two-drug combination for adults newly diagnosed with a slow-growing form of mantle cell lymphoma. The goal is to see if the drugs pirtobrutinib and rituximab can effectively control the disease while being easier to tolerate than standard…

This is the first study in people testing a new drug called LTZ-301 for adults with non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also c…

This study is testing whether a combination of two treatments can better control aggressive B-cell lymphomas that have returned or not responded to standard therapies. It combines a personalized cell therapy (CAR-T) that trains a patient's own immune cells to attack cancer, with …

This early-stage trial is testing the safety and finding the right dose of a new type of CAR-T cell therapy for people whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to other treatments. The therapy uses a patient's own modified immune cells designed to attac…

This study is creating a national registry to track how nearly 3,000 adults in Germany with various blood cancers are treated in real-world clinics. It aims to understand common treatment patterns, patient quality of life, and survival outcomes over time. The goal is to identify …